Pharmacokinetics and Pharmacodynamics Practice Questions

Q: Why is nitroglycerin used sublingually?

Terminates first-pass metabolism. **Explanation:** **1. Why the Correct Answer is Right:** Nitroglycerin (GTN) undergoes extensive **first-pass metabolism** in the liver (nearly 90-100% bioavailability is lost if swallowed). When administered sublingually, the drug is absorbed directly through the oral mucosa into the systemic circulation via the superior vena cava, bypassing the portal circulation and the liver. This ensures that a therapeutic concentration of the drug reaches the systemic circulation rapidly to exert its anti-anginal effects. **2. Analysis of Incorrect Options:** * **A. Rapid absorption:** While sublingual administration does result in rapid absorption (onset in 1–3 minutes), this is a *consequence* of the route, not the primary pharmacological reason for choosing it over oral administration. If first-pass metabolism weren't an issue, an oral dose could also be formulated for speed. * **B. Water soluble:** Nitroglycerin is actually highly **lipid-soluble**, which is what allows it to cross the mucosal membranes easily. * **C. Long acting:** Sublingual nitroglycerin is notoriously **short-acting** (duration of 10–30 minutes). For long-term prophylaxis, transdermal patches or oral isosorbide mononitrate are used. **3. High-Yield NEET-PG Clinical Pearls:** * **Drug of Choice:** Sublingual GTN is the drug of choice for **acute anginal attacks**. * **Storage:** GTN is volatile and adsorbed by plastic; it must be stored in tightly capped **amber-colored glass bottles**. * **Side Effects:** The most common side effect is a "throbbing" headache (due to meningeal vasodilation) and orthostatic hypotension. * **Contraindication:** Never co-administer with **Sildenafil** (PDE-5 inhibitors) as it can lead to severe, fatal hypotension.

Q: Which drug is highly distributed to body fat?

Thiopentone. ### Explanation The correct answer is **Thiopentone**. **1. Why Thiopentone is correct:** The distribution of a drug depends on its lipid solubility and ionization. Thiopentone is an ultra-short-acting barbiturate characterized by **extreme lipid solubility**. Upon intravenous administration, it rapidly crosses the blood-brain barrier to induce anesthesia. However, its action is terminated not by metabolism, but by **redistribution**. It moves from the highly vascular brain to less vascular but lipid-rich tissues like skeletal muscle and, eventually, **adipose tissue (body fat)**. Because fat has low blood flow, the drug accumulates there, acting as a reservoir. **2. Why the other options are incorrect:** * **Digoxin:** While it has a large volume of distribution ($V_d$), it primarily binds to **skeletal muscle** (via Na+/K+ ATPase) and heart tissue, not fat. * **Heparin:** This is a large, highly ionized (polar) molecule. It remains confined to the **plasma compartment** ($V_d \approx$ plasma volume) and does not distribute into tissues or fat. * **Mannitol:** It is a highly water-soluble (hydrophilic) sugar alcohol. It remains in the **extracellular fluid (ECF)** and does not cross cell membranes or distribute into adipose tissue. **3. NEET-PG High-Yield Pearls:** * **Redistribution:** This is the hallmark of highly lipid-soluble drugs (e.g., Thiopentone, Propofol). It explains why a patient wakes up quickly despite the drug still being present in the body. * **Volume of Distribution ($V_d$):** * Low $V_d$ (confined to plasma): Heparin, Warfarin. * Medium $V_d$ (ECF): Mannitol, Aminoglycosides. * High $V_d$ (Tissue binding): Digoxin, Chloroquine (highest $V_d$). * **Clinical Note:** In obese patients, Thiopentone can have a prolonged recovery time due to extensive accumulation in the large fat reservoir.

Q: Loading dose primarily depends on which pharmacokinetic parameter?

Volume of distribution. **Explanation:** The **Loading Dose (LD)** is the initial higher dose of a drug given at the beginning of a course of treatment before dropping to a lower maintenance dose. Its primary purpose is to rapidly achieve the **target therapeutic plasma concentration ($C_p$)**. **1. Why Volume of Distribution ($V_d$) is correct:** The loading dose is mathematically defined by the formula: $$\text{Loading Dose} = \frac{V_d \times \text{Target } C_p}{\text{Bioavailability (F)}}$$ Since the goal is to "fill up" the body's various compartments (tissues and plasma) to reach a specific concentration, the amount of drug required is directly proportional to the space it occupies ($V_d$). If a drug has a high $V_d$ (extensive tissue binding), a larger loading dose is needed. **2. Why the other options are incorrect:** * **Clearance (B):** This determines the **Maintenance Dose**. Clearance relates to how fast the drug is removed, which dictates how much must be replaced to maintain a steady state. * **Rate of administration (C):** This affects the peak plasma concentration and potential toxicity (especially with IV bolus) but does not determine the total dose required to reach steady state. * **Half-life (D):** This determines the **time taken** to reach steady state (usually 4–5 half-lives) and the dosing interval, but not the magnitude of the loading dose itself. **High-Yield Clinical Pearls for NEET-PG:** * **Loading Dose:** "Fills the tank" (Depends on $V_d$). * **Maintenance Dose:** "Replaces the leak" (Depends on Clearance). * **Clinical Example:** Digoxin and Phenytoin often require loading doses due to their large $V_d$ and the need for rapid effect. * **Note:** In patients with renal or hepatic failure, the loading dose usually remains the same (unless $V_d$ is altered), but the maintenance dose must be decreased.

Q: Which of the following medications inhibits the effect of oral contraceptive pills?

Rifampicin. **Explanation:** **1. Why Rifampicin is the Correct Answer:** Rifampicin is a potent **inducer of Cytochrome P450 (CYP450) enzymes**, specifically the CYP3A4 isoform. Oral contraceptive pills (OCPs) contain estrogen and progestin, which are metabolized by these liver enzymes. When Rifampicin induces these enzymes, it accelerates the metabolism and clearance of the hormones, leading to sub-therapeutic plasma levels. This results in **contraceptive failure** and breakthrough bleeding. It is the most notorious drug for this interaction. **2. Why the Other Options are Incorrect:** * **B. Cimetidine:** This is a potent **enzyme inhibitor**. It would typically increase the plasma levels of drugs metabolized by the liver, potentially increasing the side effects of OCPs rather than inhibiting their efficacy. * **C. Ethambutol:** Unlike Rifampicin, Ethambutol is an antitubercular drug that does not significantly affect the hepatic microsomal enzyme system. It has no documented interaction with OCPs. * **D. Propranolol:** This is a non-selective beta-blocker. While it is metabolized by the liver, it does not induce or inhibit enzymes in a way that would diminish the clinical effect of OCPs. **3. High-Yield Clinical Pearls for NEET-PG:** * **The "Inducer" Mnemonic:** Remember **GPRS Cell Phone** (Griseofulvin, Phenytoin, Rifampicin, Smoking, Carbamazepine, Phenobarbitone) as the classic CYP450 inducers. * **Patient Counseling:** Patients on OCPs starting Rifampicin therapy (e.g., for Tuberculosis) must be advised to use an **alternative/barrier method** of contraception. * **Broad Spectrum:** Rifampicin is a "pan-inducer," affecting almost all CYP families (1A2, 2C9, 2C19, 3A4).

Q: For drugs with first-order kinetics, the time required to achieve steady-state levels can be predicted from which pharmacokinetic parameter?

Half-life. **Explanation:** The time required to reach steady-state concentration ($C_{ss}$) is a function of the drug's **half-life ($t_{1/2}$)**. For drugs following first-order kinetics, a constant fraction of the drug is eliminated per unit of time. **Why Half-life is Correct:** Steady-state is achieved when the rate of drug administration equals the rate of drug elimination. Mathematically, it takes approximately **4 to 5 half-lives** to reach steady-state, regardless of the dose or frequency of administration (provided they are constant). * 1 $t_{1/2}$ = 50% of $C_{ss}$ * 2 $t_{1/2}$ = 75% of $C_{ss}$ * 3 $t_{1/2}$ = 87.5% of $C_{ss}$ * **4-5 $t_{1/2}$ = >95% of $C_{ss}$ (Clinically considered steady-state)** **Why Other Options are Incorrect:** * **Volume of Distribution ($V_d$):** Determines the **loading dose** required to achieve a target plasma concentration immediately, but it does not dictate the time to reach steady-state. * **Clearance ($CL$):** Determines the **maintenance dose** required to maintain $C_{ss}$, but the time to reach that state remains dependent on the half-life ($t_{1/2} = 0.693 \times V_d / CL$). * **Loading Dose:** This is used to achieve therapeutic levels rapidly, but it does not change the inherent time the body takes to reach a true kinetic steady-state. **High-Yield Clinical Pearls for NEET-PG:** * **Rule of Thumb:** It takes 4-5 half-lives to reach steady-state and **4-5 half-lives to completely eliminate** a drug from the body after stopping it. * **Zero-order kinetics:** Unlike first-order, drugs like phenytoin or alcohol do not have a constant half-life; therefore, steady-state is unpredictable and dose-dependent. * **Steady-state concentration ($C_{ss}$)** is directly proportional to the infusion rate and inversely proportional to clearance.

Q: Which of the following statements about phenytoin is true?

It follows zero-order kinetics.. ### Explanation **1. Why Option A is Correct:** Phenytoin exhibits a unique pharmacokinetic profile known as **Capacity-Limited Metabolism** (or Michaelis-Menten kinetics). At low therapeutic concentrations, it follows first-order kinetics. However, the hepatic enzymes responsible for its metabolism (CYP2C9 and CYP2C19) become saturated even at doses within the therapeutic range. Once saturated, the rate of metabolism becomes constant regardless of the plasma concentration, shifting to **Zero-Order Kinetics**. This is clinically significant because small dose increments can lead to disproportionately large increases in plasma levels, potentially causing toxicity. **2. Why the Other Options are Incorrect:** * **Option B:** Phenytoin is highly **teratogenic**. It is associated with **Fetal Hydantoin Syndrome**, characterized by craniofacial dysmorphism, hypoplastic phalanges/nails, and growth retardation. * **Option C:** Phenytoin is **extensively metabolized** in the liver (primarily by parahydroxylation). Less than 5% of the drug is excreted unchanged in the urine. * **Option D:** Phenytoin is a potent **Inducer of Microsomal Enzymes** (CYP450). This leads to significant drug-drug interactions, such as reducing the efficacy of oral contraceptives, warfarin, and steroids. **3. High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Range:** 10–20 µg/mL. * **Adverse Effects (Mnemonic: HOT MALAI):** **H**irsutism, **O**steomalacia, **T**eratogenicity, **M**egaloblastic anemia (folate deficiency), **A**taxia, **L**ymphadenopathy, **A**rrhythmias (on rapid IV), **I**nsulin inhibition (hyperglycemia), and **Gum Hyperplasia**. * **Fosphenytoin:** A water-soluble prodrug of phenytoin used for IV administration to avoid the risk of "Purple Glove Syndrome" and local irritation.

Question 1

Which of the following is characteristic of drugs exhibiting zero-order kinetics of elimination?

Accepted Answer

Their elimination half-life is independent of the dose.

Answer

They are more common than drugs following first-order kinetics.

Answer

Their concentration decreases exponentially with time.

Answer

A plot of drug concentration versus time is linear.

Question 2

Why is nitroglycerin used sublingually?

Accepted Answer

Terminates first-pass metabolism

Answer

Rapid absorption

Answer

Water soluble

Answer

Long acting

Question 3

Which drug is highly distributed to body fat?

Accepted Answer

Thiopentone

Answer

Digoxin

Answer

Heparin

Answer

Mannitol

Question 4

Procainamide infusion is initiated. Its half-life is 2 hours. The infusion begins at 9:00 a.m. and ends at 1:00 p.m. on the same day. At 1:00 p.m., the blood concentration is found to be 3 mg/L. What is the probable steady-state concentration after 2 days of infusion?

Accepted Answer

4 mg/L

Answer

3 mg/L

Answer

6 mg/L

Answer

15 mg/L

Question 5

Loading dose primarily depends on which pharmacokinetic parameter?

Accepted Answer

Volume of distribution

Answer

Clearance

Answer

Rate of administration

Answer

Half-life

Question 6

Arrange the following drugs according to their half-life in increasing order: 1. Amiodarone 2. Adenosine 3. Esmolol 4. Omeprazole

Accepted Answer

2-3-4-1

Answer

1-2-4-3

Answer

2-3-1-4

Answer

4-3-1-2

Question 7

Which of the following medications inhibits the effect of oral contraceptive pills?

Accepted Answer

Rifampicin

Answer

Cimetidine

Answer

Ethambutol

Answer

Propranolol

Question 8

An 18-year-old man with non-penicillinase-producing gonococcal urethritis is given an injection of penicillin and probenecid. What is the mechanism by which probenecid enhances penicillin's efficacy?

Accepted Answer

Increases the half-life and serum level by decreasing the renal excretion of penicillin.

Answer

Promotes the entry of penicillin into bacteria.

Answer

Prolongs the duration of action by affecting the liver metabolism of penicillin.

Answer

Decreases bacterial resistance by inhibiting penicillinase production.

Question 9

For drugs with first-order kinetics, the time required to achieve steady-state levels can be predicted from which pharmacokinetic parameter?

Accepted Answer

Half-life

Answer

Volume of distribution

Answer

Clearance

Answer

Loading dose

Question 10

Which of the following statements about phenytoin is true?

Accepted Answer

It follows zero-order kinetics.

Answer

It is not teratogenic.

Answer

It is excreted unchanged in urine.

Answer

It does not induce microsomal enzymes.

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?